Furthermore, we used SP600125 (JNK3 inhibitor, 30 mg/kg, i.p) to inject APP/PS1 mice with or without PBM treatment for 30 days to illustrate whether PBM alleviates multiple pathological features associated with AD models by regulating JNK3. Here, MAPK10 is linked to Alzheimer disease.